Results 11 to 20 of about 86,774 (206)
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative Children [PDF]
The Journal of Infectious Diseases, 2022 Abstract Background This United States-based study compared 2 candidate vaccines: RSV/ΔNS2/Δ1313/I1314L, attenuated by NS2 gene-deletion and temperature-sensitivity mutation in the polymerase gene; and RSV/276, attenuated by M2-2 deletion. Methods
Cunningham, Coleen K +23 more
openaire +5 more sources
Global molecular diversity of RSV – the “INFORM RSV” study [PDF]
BMC Infectious Diseases, 2020 Abstract Background Respiratory syncytial virus (RSV) is a global cause of severe respiratory morbidity and mortality in infants. While preventive and therapeutic interventions are being developed, including antivirals, vaccines and monoclonal antibodies, little is known about the global molecular epidemiology of RSV.
Langedijk, Annefleur C. +28 more
openaire +5 more sources
The path to an RSV vaccine [PDF]
Current Opinion in Virology, 2013 Respiratory syncytial virus (RSV) is the greatest remaining unmet infant vaccine need in developed countries and an important unmet infant vaccine need worldwide. More than 40 years of effort have yet to result in a licensed RSV vaccine for humans.
Christine A, Shaw +7 more
openaire +2 more sources
Role and Virology of RSV and RSV RNA Polymerase
The FASEB Journal, 2021 Respiratory syncytial virus (RSV) is a highly contagious, respiratory virus that commonly infects children under the age of five. RSV infections can present as cold‐like symptoms which include a runny nose, coughing, and fever among other common symptoms; however, RSV can cause more severe infections such as bronchiolitis and ...
Tina Link +5 more
openaire +1 more source
The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya [PDF]
, 2009 Background Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infection in infants. The rate of decay of RSV-specific maternal antibodies (RSV-matAb), the factors affecting cord blood levels, and the relationship between ...
Nokes D. James +26 more
core +1 more source
Adult respiratory syncytial virus (RSV) session [PDF]
01-RSV-Adults-Kotton-508 ...
core +10 more sources
Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom. [PDF]
, 2006 Respiratory syncytial virus (RSV) infection produces more severe disease and increased hospitalization rates in high-risk babies. The monoclonal antibody palivizumab offers protection against complications, and the first of five monthly doses should be ...
Nguyen-Van-Tam, JS +7 more
core +1 more source
Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995-March 1998. [PDF]
, 2002 Estimates of the number of hospitalizations attributable to specific pathogens are required to predict the potential impact of vaccination. All hospital admissions for lower respiratory tract infection (LRI) in children < 5 years in England in 1995-8 ...
Edmunds, WJ +4 more
core +1 more source
Antiviral therapy in current clinical practice: Respiratory virus infections
Sri Lankan Journal of Infectious Diseases, 2023 No abstract ...
S. N. Janage
doaj +1 more source
Journal of Clinical Virology, 2020 Respiratory syncytial virus (RSV) immunoprophylaxis (IP) has been shown to reduce RSV hospitalization rates in high-risk infants; however, it is unclear whether RSV IP is associated with increased risk of non-RSV disease, particularly non-RSV hospitalizations.
Adam, Bloomfield +3 more
openaire +2 more sources